CT
The startup develops DNA-binding agents that reduce the severe side effects associated with traditional chemotherapy drugs. By providing healthcare providers with a new class of therapeutic options, the company aims to improve patient quality of life during cancer treatment.
Updated 4 months ago
Funding
$26.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops DNA-binding agents that reduce the severe side effects associated with traditional chemotherapy drugs. By providing healthcare providers with a new class of therapeutic options, the company aims to improve patient quality of life during cancer treatment.